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Introduction 
Of the many factors that have been implicated from time 
to time in the pathophysiology of migraine, none seems 
to have a better claim than 5-hydroxytryptamine (5-HT; 
serotonin). Advances in the understanding of the role of 
5-HT in migraine and in the pharmacology of this amine 
have now resulted in the development of the drug, suma- 
triptan, for the treatment of migraine. Since this drug is 
a selective agonist at a particular type of 5-HTl-like re- 
ceptors [5], it is desirable to sketch the current views on 
the classification and nomenclature of 5-HT receptors. 
5-HT receptor classification 
More than three decades ago Gaddum and Picarelli [3] 
reported that 5-HT stimulates two different ypes of re- 
ceptor - "D" [phenoxybenzamine (dibenzyline)-sensi- 
tive] and "M" (morphine-sensitive) - which are present 
on the intestinal smooth muscle and intramural neurons, 
respectively. Already in the early 70's, it was, however, 
recognized that some pharmacological effects of 5-HT, 
for example vasoconstriction in the canine common ca- 
rotid bed [6], are mediated by "atypical" receptors. Sub- 
sequently, it was demonstrated that two different bind- 
ing sites, 5-HTt and 5-HT2, exist in the rat brain mem- 
branes [4]. In 1986, Bradley et al. [1] proposed a new 
classification where the receptors for 5-HT were catego- 
rized into three main types, 5-HT~-like (previously refer- 
red to as "atypical"), 5-HT2 (previously referred to as 
"D") and 5-HT3 (previously referred to as "M"). More 
recently, 5-HT4 receptors have also been described [2]. 
Table 1 lists the agonists and antagonists at and the 
functional responses mediated by the different 5-HT re- 
ceptors. It has to be emphasized that only 5-HT2 and 5- 
HT3 receptors have so far been well characterized using 
selective antagonists. No such substances are yet avail- 
able for 5-HTl-like and 5-HT4 receptors. The 5-HTl-like 
receptors, having a nanomolar affinity for 5-HT, are het- 
erogeneous in nature but the exact association with the 
5-HT1 binding site subtypes is still unclear since suffi- 
Table 1. Agonists and antagonists and some functional responses mediated by 5-HT receptors 
Receptor Agonists Antagonists Binding Second Some functional responses 
type site messenger 
5-HTl-like 5-HT Methiothepin ~', 5-HT~ See Table 2 
5-CT methysergide ~ 
5-HT2 5-HT, Ketanserin, 5-HT2 
c~-methyl-5HT cyproheptadine, 
methysergide, 
methiothepin 
MDL72222, 5-HT3 K ' 
ICS 205930, 
granisetron, 
ondansetron 
ICS 205930 Not yet Positive 
(high concert- found coupling 
trations) to AC 
5-HT3 5-HT, 
2-methyl-5HT 
5-HT4 5-HT, 
renzapride, 
5-CHBO-T 
PIte-specific 
PLA-C 
Contraction of various vascular, 
gastrointestinal and bronchial 
smooth muscles, platelet aggregation, 
head twitch 
Membrane depolarization, dermal pain 
and flare response 
Gastrokinetic action, cholinergically- 
mediated guinea-pig ileum contraction, 
myocardial stimulation in the pig 
" Non-selective antagonist (also blocks 5-HT2 receptors) 
AC, adenylyl cyclase; K ~ , potassium channel; ICS 205930; (3c~-tropanyl)-lH-indole-3-carboxylic 
mine; MDL7222, laH,3(x,5o, H-tropan-3yl-3,5-dichlorobenzoate: PIte, phosphoinositide: PLA-C, 
tryptamine 
acid ester: 5-CHBO-T, 5-methoxytrypta- 
phospholipase C: 5-CT, 5-carboxamido- 
Table 2. Putative subdivisions of the 5-HTl-like receptors: agonists and antagonists and some functional responses 
Subtype Agonists Antagonists Binding site Second messenger Some functional responses 
5-HT1A 5-HT, 8-OH- Cyanopindolol, 5-HTIA Negative coupling Behavioural changes, centrally 
DPAT, 5-HT, methysergide, to AC, K ÷ evoked hypotensive r sponse 
RU 24969 methiothepin 
5-HTIB RU 24969,  Cyanopindolol, 5-HTm 
5-CT, 5-HT methiothepin, 
methysergide 
5-HTlc a 5-HT Mesulergine, 5-HTm 
methiothepin, 
methysergide 
Methiothepin 
$37 
Negative coupling 
to AC 
PIte-specific 
PLA-C 
5-HTID 5-CT, 5-HT, 5-HT1D Negative coupling 
sumatriptan to AC 
5-HTlx b 5-CT, 5-HT, Methiothepin, Not yet Not yet 
AH25086 c, methysergide d found e known 
sumatriptan, 
8-OH-DPAT, 
RU 24969 
5-HTly b 5-CT, 5-HT Methiothepin, Not yet Not yet 
methysergide found e known 
Autoreceptor in the rat brain 
Not yet convincingly 
demonstrated 
Not yet convincingly 
demonstrated 
Contraction ofcephalic arteries 
(basilar, pial) and arteriovenous 
anastomoses in the carotid region, 
decrease of neuronal noradrenaline 
release 
Vascular smooth muscle relaxation, 
hypotension, tachycardia inthe cat 
a Shows little difference from the 5-HT2 receptor 
b The receptor subtype isas yet unnamed and this name has been used for convenience to distinguish between the two unnamed 5-HTl-like 
receptors 
c Ligand binding profile is not yet reported 
d Partial agonist 
e Does not correlate with 5-HT1A, 5-HT1B, 5-HTlc or 5-HTm binding sites 
AC, adenylyl cyclase; AH25086, 3-aminoethyl-N-methyl-lH-indole-5-methane carboxamide; 5-CT, 5-carboxamidotryptamine; K +, potas- 
sium channel; 8-OH-DPAT, 8-hydroxy-2-(di-n-propylamino)tetralin; PIte, phosphoinositide; PLA-C, phospholipase C; RU 24969, 5- 
methoxy-3-(1,2, 3,6-tetrahydropyridin-4-yl)-1H-indole 
ciently selective drugs are not yet available, except for 
the 5-HT1A site (Table 2; [5]). 
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